GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Oragenics Inc.
Oragenics is a biotech company developing vaccines. Its stock price is highly volatile and driven by news about the progress of clinical trials. The chart is a speculative story, where the success or failure of the trial is crucial.
Share prices of companies in the market segment - Pharma infections
Oragenics, Inc. is a biopharmaceutical company developing vaccines to combat infectious diseases, including new coronavirus strains. We've categorized it as a Pharmaceutical: Infections stock. The chart below shows how investors value companies working in vaccine development.
Broad Market Index - GURU.Markets
Oragenics is a biotech company developing vaccines against infectious diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
OGEN - Daily change in the company's share price Oragenics Inc.
Oragenics, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about the clinical trials of its vaccines and therapeutics.
Daily change in the price of a set of shares in a market segment - Pharma infections
Oragenics develops vaccines against infectious diseases, including new coronavirus strains. The vaccine sector is highly volatile and driven by news about clinical trials and pandemics. The chart below reflects the average fluctuations in this industry, providing context for evaluating OGEN stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Oragenics is a biotech company developing vaccines against infectious diseases. Its shares are extremely sensitive to news about clinical trials and pandemics. This event-driven volatility is a clear example of how biotech influences the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Oragenics Inc.
Oragenics, Inc.'s year-over-year performance tells the story of its quest for the next breakthrough. Its 12-month market cap reflects its strategic pivot to developing an intranasal COVID-19 vaccine. Its valuation is a high-risk bet that its approach will find a niche in the booster vaccine market.
Annual dynamics of market capitalization of the market segment - Pharma infections
Oragenics, Inc. is an early-stage biotech company developing vaccines. Its stock performance is entirely dependent on the results of preclinical and clinical trials. The chart reflects the high risks and speculative nature typical of this sector, where a single success or failure can dramatically change the valuation.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Oragenics, a biopharmaceutical company developing vaccines against infectious diseases, including COVID-19, has found itself in the spotlight during the pandemic. Its year-over-year market capitalization is highly volatile, dependent on news about clinical trials and competition from pharmaceutical giants.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Oragenics Inc.
Oragenics is a biotech company developing vaccines. Its monthly performance is entirely dependent on progress in its clinical trials. News of its infectious disease vaccine trial results is the main driver of its value.
Monthly dynamics of market capitalization of the market segment - Pharma infections
The development of vaccines and drugs for infectious diseases is a high-risk area, where investor sentiment can shift with every news about pandemics or trials. The dynamics of this sector, shown in the chart, reflect this volatility. A company like Oragenics operates in this unpredictable environment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Oragenics, a biopharmaceutical company developing vaccines, lives in a world of news about clinical trials and pandemics. Its stock price is completely uncorrelated with the market and can change dramatically in a day based on regulatory announcements.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Oragenics Inc.
Oragenics, a biotech company developing vaccines against infectious diseases, has been in the spotlight since the pandemic. Its weekly stock price is a direct response to preclinical and clinical trial data, as well as funding news for its developments.
Weekly dynamics of market capitalization of the market segment - Pharma infections
Oragenics develops vaccines against infectious diseases, including COVID-19. Its stock price is entirely dependent on the progress of clinical trials and epidemiological updates. The chart clearly demonstrates how independent its path is from general trends in the pharmaceutical industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Oragenics develops vaccines. Its stock price is entirely dependent on the progress of clinical trials and the epidemiological situation. The chart clearly demonstrates how independent its path is from overall stock market trends.
Market capitalization of the company, segment and market as a whole
OGEN - Market capitalization of the company Oragenics Inc.
Oragenics' market capitalization chart reflects investors' assessments of its vaccine and pharmaceutical developments. Its dynamics tell a story of shifting focus, from oral health to COVID-19 vaccines. Its extremely low price and high volatility reflect its ongoing search for a successful product and the high risk of clinical failure.
OGEN - Share of the company's market capitalization Oragenics Inc. within the market segment - Pharma infections
Oragenics develops vaccines against infectious diseases. Its market share in the pharmaceutical sector is small and highly dependent on clinical trial results. Its market capitalization reflects investor confidence in its platform and its leading candidates, including an intranasal COVID-19 vaccine.
Market capitalization of the market segment - Pharma infections
This chart shows the total value of the entire pharmaceutical sector focused on infectious diseases. For Oragenics, a vaccine developer, this line is a map of global health. Its dynamics reflect the world's willingness to invest in infection prevention and control, a key focus for the company.
Market capitalization of all companies included in a broad market index - GURU.Markets
Oragenics develops vaccines against infectious diseases. Its market capitalization compared to pharmaceutical giants reflects its scientific research and potential to combat new and old threats.
Book value capitalization of the company, segment and market as a whole
OGEN - Book value capitalization of the company Oragenics Inc.
Oragenics develops vaccines against infectious diseases. Its book value represents its financial resources for research. It consists of cash, which allows the company to conduct preclinical and clinical development. How has this vital capital changed? The chart below shows.
OGEN - Share of the company's book capitalization Oragenics Inc. within the market segment - Pharma infections
Oragenics, Inc. develops vaccines. Its scientific activities require a substantial resource base: laboratories for development and preclinical research, as well as investments in manufacturing processes. The chart shows the company's share of the physical R&D infrastructure required to create new vaccines.
Market segment balance sheet capitalization - Pharma infections
Oragenics is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are knowledge- and capital-intensive. Oragenics focuses on vaccine development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Oragenics' assets are not factories, but capital and a scientific base for developing vaccines against infectious diseases, including an intranasal vaccine for COVID-19. Its book value reflects its financial resources for preclinical and clinical trials.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Oragenics Inc.
Oragenics is a biopharmaceutical company developing vaccines. Its market capitalization is highly volatile, reflecting investor expectations for the success of its clinical trials, especially in light of the global focus on infectious diseases.
Market to book capitalization ratio in a market segment - Pharma infections
Oragenics is a biotech company developing vaccines. Its valuation on this chart depends heavily on the success of its clinical trials and its ability to compete with pharmaceutical giants, a very challenging task.
Market to book capitalization ratio for the market as a whole
Oragenics develops vaccines, including against infectious diseases. The market value of such companies soars on expectations of successful clinical trials. This chart shows how strongly biotech company valuations can depend on the news environment and overall investor risk appetite.
Debts of the company, segment and market as a whole
OGEN - Company debts Oragenics Inc.
Oragenics, a biopharmaceutical company developing vaccines, including intranasal ones, relies entirely on external funding for its preclinical and clinical trials. This chart illustrates the high financial barrier and risk associated with developing new vaccines.
Market segment debts - Pharma infections
Oragenics is a biopharmaceutical company developing vaccines to combat infectious diseases, including new variants of COVID-19. This chart shows how a small company finances its expensive and risky R&D in the highly competitive field of vaccine development, dominated by pharmaceutical giants.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Oragenics Inc.
Oragenics develops vaccines against infectious diseases, including COVID-19. Vaccine development is an extremely lengthy, expensive, and risky process, requiring large-scale clinical trials. This chart illustrates how heavily the company relies on debt to fund its vital but capital-intensive research.
Market segment debt to market segment book capitalization - Pharma infections
Oragenics is a biopharmaceutical company developing vaccines against infectious diseases. Vaccine development is a long and expensive process. This chart shows how the company finances its research. It relates its debt structure to the overall financial picture in the capital-intensive biotech sector.
Debt to book value of all companies in the market
Oragenics, Inc. develops vaccines against infectious diseases. Vaccine development and clinical trials are extremely expensive and risky, requiring massive capital investment. How heavily is the company reliant on debt? This graph of total debt in the economy helps assess the riskiness of its financial strategy.
P/E of the company, segment and market as a whole
P/E - Oragenics Inc.
Oragenics is a biopharmaceutical company developing vaccines against infectious diseases. This chart shows how investors valued the company during and after the pandemic. The valuation soared on news of the COVID-19 vaccine's development and was adjusted based on research progress.
P/E of the market segment - Pharma infections
Oragenics, Inc. is a biopharmaceutical company developing vaccines to combat infectious diseases. This chart illustrates the average valuation in the pharmaceutical sector, where vaccine development carries high risks but also offers enormous potential for success and government contracts.
P/E of the market as a whole
Oragenics, Inc. is a biopharmaceutical company developing vaccines to combat infectious diseases. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether OGEN's valuation reflects confidence in its vaccine platform or whether it is moving in line with overall sector sentiment, particularly in the wake of the pandemic.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Oragenics Inc.
Oragenics is a biopharmaceutical company developing vaccines against infectious diseases. Its future depends on the success of clinical trials and its ability to compete in the vaccine market. This chart shows how investors assess the scientific potential and commercial prospects of its vaccine candidates in the fight against new and existing threats.
%20P%2FE%20Oragenics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Oragenics-Inc.&v=1772643186337 "Chart of the company's future (projected) P/E Oragenics Inc.")
Future (projected) P/E of the market segment - Pharma infections
Oragenics develops vaccines to combat infectious diseases. The success of such companies depends on the results of clinical trials and the ability to quickly bring the product to market. The chart reflects future profit forecasts for the sector, helping to understand the high expectations investors have for Oragenics' scientific developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-infections&v=1772643186372 "Future (projected) P/E graph of the market segment - Pharma infections")
Future (projected) P/E of the market as a whole
Oragenics is a biotech company developing vaccines against infectious diseases. Vaccine development is a long, expensive, and risky process. This overall risk appetite chart is an indicator of investor willingness to fund vaccine projects, especially in the wake of the COVID-19 pandemic.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772643186398 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Oragenics Inc.
Oragenics, Inc. is a biopharmaceutical company developing vaccines to combat infectious diseases, including COVID-19. Its financial performance is based on clinical trial expenses. This chart shows investments in the development of new vaccines, which is capital-intensive and risky, but potentially highly profitable.
Profit of companies in the market segment - Pharma infections
Oragenics, Inc. is a biopharmaceutical company developing vaccines to combat infectious diseases. Its research is focused on creating new, more effective vaccines. This chart shows the overall profitability of the infectious disease pharmaceutical sector, which has received significant attention and investment following the COVID-19 pandemic.
Overall market profit
Oragenics, Inc. is a biopharmaceutical company developing vaccines against infectious diseases. The demand for vaccines can surge during pandemics, but is generally driven by public health needs. This market is independent of economic cycles, as can be seen in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Oragenics Inc.
Oragenics develops next-generation vaccines, including those against infectious diseases. The company's future profitability depends entirely on the success of its preclinical and clinical trials. This chart reflects analysts' speculative expectations for its vaccine candidates.
%20profit%20of%20the%20company%20Oragenics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Oragenics-Inc.&v=1772643186518 "Graph of future (projected) profit of the company Oragenics Inc.")
Future (predicted) profit of companies in the market segment - Pharma infections
Oragenics is a biopharmaceutical company developing vaccines against infectious diseases. Its primary focus is developing an intranasal COVID-19 vaccine, which could provide broader protection. This chart shows revenue expectations for the pharmaceutical sector, providing context for evaluating Oragenics' vaccine platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-infections&v=1772643186566 "Graph of future (predicted) profits of companies in a market segment - Pharma infections")
Future (predicted) profit of the market as a whole
Oragenics, Inc. is a biopharmaceutical company developing vaccines against infectious diseases. Its prospects depend on the success of clinical trials and government contracts. This economic outlook influences government healthcare budgets and their willingness to fund vaccine development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772643186591 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Oragenics Inc.
Oragenics is a biopharmaceutical company developing vaccines against infectious diseases. There is no revenue during the development stage. This chart reflects investors' speculative expectations regarding its vaccine candidates and their ability to successfully complete clinical trials.
P/S market segment - Pharma infections
Oragenics is a biotech company developing vaccines against infectious diseases. Its primary focus is developing an intranasal COVID-19 vaccine, which could provide broader protection and be easier to administer. This chart reflects the average revenue estimate for the sector, helping to gauge the market's perception of the potential of Oragenics' developments.
P/S of the market as a whole
Oragenics is a biopharmaceutical company developing vaccines against infectious diseases, including new COVID-19 vaccine candidates. This chart highlights that the valuation of such companies can be highly volatile and depend on news about clinical trials and the epidemiological situation, rather than current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Oragenics Inc.
Oragenics is a biopharmaceutical company developing vaccines to combat infectious diseases, including COVID-19. Its revenue valuation is crucial. It reflects investor expectations for the success of its vaccine candidates in clinical trials and its ability to carve out a niche in the highly competitive vaccine market, potentially as a booster or for specific populations.
%20P%2FS%20Oragenics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Oragenics-Inc.&v=1772643186756 "The graph of the company's future (projected) P/S Oragenics Inc.")
Future (projected) P/S of the market segment - Pharma infections
Oragenics develops and commercializes antibiotics and vaccines. This chart compares the company's estimated future sales with industry expectations. It shows how investors view its pipeline, including new approaches to combating infectious diseases and the potential of its vaccine programs in light of global health threats.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20infections&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-infections&v=1772643186832 "Future (projected) P/S market segment graph - Pharma infections")
Future (projected) P/S of the market as a whole
Oragenics develops vaccines against infectious diseases, including an intranasal COVID-19 vaccine. The company's future depends on the success of its clinical programs in a highly competitive environment. This graph of investor expectations reflects their belief that the need for new and improved vaccines will continue.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772643186873 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Oragenics Inc.
The chart illustrates the financial activity of Oragenics, Inc., a biotechnology company developing vaccines against infectious diseases. Being in clinical development, the company has no commercial revenue from sales. Any income likely comes from grants or partnerships.
Sales of companies in the market segment - Pharma infections
Oragenics, Inc. is a biopharmaceutical company developing vaccines against infectious diseases. Being in the development stage, it has no sales revenue yet. Its future revenue is entirely dependent on the success of its vaccine candidates, which is typical for companies in this high-risk but potentially high-reward industry.
Overall market sales
Oragenics, Inc. is a biopharmaceutical company developing vaccines against infectious diseases. Its success depends on the results of clinical trials and the epidemiological situation. This general economics chart is not relevant to a company whose mission is to prevent diseases, where demand is driven by public health threats.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Oragenics Inc.
Oragenics, Inc. is a biopharmaceutical company developing vaccines to combat infectious diseases. Its future revenue depends on the success of clinical trials and the receipt of vaccine supply contracts. This chart reflects analyst expectations for the commercial potential of its vaccine candidates in the context of an ever-changing epidemiological environment.
%20sales%20of%20the%20company%20Oragenics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Oragenics-Inc.&v=1772643187060 "Schedule of future (projected) sales of the company Oragenics Inc.")
Future (projected) sales of companies in the market segment - Pharma infections
Oragenics, Inc. develops vaccines against infectious diseases. This chart shows the outlook for the pharmaceutical market. Will the high interest and funding in vaccine development continue after the pandemic, supporting growth in the entire sector? This reflects the overall sentiment in the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-infections&v=1772643187107 "Schedule of future (projected) sales of companies in the market segment - Pharma infections")
Future (projected) sales of the market as a whole
Oragenics is a biopharmaceutical company developing vaccines against infectious diseases. Its success depends entirely on the results of clinical trials and regulatory approvals, as well as the epidemiological situation. General economic cycles, as shown in this chart, do not affect humanity's need for effective vaccines to combat pandemics.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772643187157 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Oragenics Inc.
Oragenics is a biopharmaceutical company developing vaccines against infectious diseases. This chart reflects its financial performance at the preclinical and early clinical trial stages. Profitability is a future goal and depends entirely on the successful development and potential commercialization of vaccines, which requires significant investment and time.
Market segment marginality - Pharma infections
Oragenics, Inc. is a biopharmaceutical company developing vaccines to combat infectious diseases. This chart reflects its financial position at the R&D stage, where profitability depends entirely on the success of its vaccine candidates in clinical trials and regulatory approval, a lengthy and capital-intensive process.
Market marginality as a whole
Oragenics, Inc. is a biotechnology company developing vaccines against infectious diseases. Its value is highly dependent on the success of clinical trials and the epidemiological situation. This gross profitability chart reflects the overall economic situation, which influences public and private funding for vaccine development.
Employees in the company, segment and market as a whole
Number of employees in the company Oragenics Inc.
Oragenics is an early-stage biotech company developing vaccines against infectious diseases. Its very small staff consists of key scientists and managers who outsource most of the research. This graph shows the compact team working to advance its candidates through the preclinical and early clinical stages.
Share of the company's employees Oragenics Inc. within the market segment - Pharma infections
Oragenics is a biotechnology company developing vaccines against infectious diseases. The vaccine development process, from research to clinical trials, is lengthy and knowledge-intensive. This chart shows the company's market share, reflecting the scale of its R&D program and the stage of development of its vaccine candidates.
Number of employees in the market segment - Pharma infections
Oragenics, Inc. is a biopharmaceutical company developing vaccines against infectious diseases, including new variants of COVID-19. The chart illustrates employment in the infectious disease pharmaceutical sector. The constant mutation of viruses requires the development of next-generation vaccines, which is what Oragenics is working on.
Number of employees in the market as a whole
Oragenics is a biotech company developing vaccines against infectious diseases. Its activities have gained particular importance in recent years. The company's growth depends on research advances and the epidemiological situation. It represents a sector where employment is a direct investment in global health security, regardless of the overall trends on this chart.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Oragenics Inc. (OGEN)
Oragenics is a biotech company focused on developing vaccines (e.g., for COVID) and treating infectious diseases. This chart shows how the market values their R&D. It reflects the market value per scientist, which is a bet on the success of their preclinical and clinical programs in a highly competitive field.
%20of%20the%20company%20Oragenics%20Inc.%20(OGEN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Oragenics-Inc.-OGEN&v=1772643187790 "Chart of market capitalization per employee (in thousands of dollars) of the company Oragenics Inc. (OGEN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma infections
Oragenics (OGEN) is a biotech company developing vaccines against infectious diseases, including COVID-19. In the vaccine development space, this chart shows how the market views their scientific platform. Sharp price movements can be associated with news of the start or successful completion of the next phase of clinical trials for their vaccine candidates.
%20by%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-infections&v=1772643187855 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma infections")
Market capitalization per employee (in thousands of dollars) for the overall market
Oragenics is a biopharmaceutical company developing vaccines against infectious diseases. Its valuation often depends on news about disease outbreaks and progress in clinical trials. The chart shows a high valuation per employee, as a successful vaccine could have global demand and generate huge revenue.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772643187916 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Oragenics Inc. (OGEN)
Oragenics is an early-stage, preclinical biotech company developing vaccines (including for COVID-19) and treatments for infectious diseases. This chart shows the net loss per employee. It reflects that each scientist at the company represents an R&D investment, funded to test scientific hypotheses.
%20Chart%20Oragenics%20Inc.%20(OGEN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Oragenics-Inc.-OGEN&v=1772643188031 "Company Profit Per Employee (in thousands of dollars) Chart Oragenics Inc. (OGEN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma infections
Oragenics, Inc. is a biopharmaceutical company developing vaccines against infectious diseases. In the vaccine business, per-employee productivity can increase dramatically after a product's approval and launch. This chart tracks the dynamics of this metric, which is key to assessing the commercial potential of their developments.
%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-infections&v=1772643188098 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma infections")
Profit per employee (in thousands of dollars) for the market as a whole
Oragenics is a biotech company focused on infectious diseases. Previously, they were working on a COVID vaccine, and now they're working on a treatment for the side effects of chemotherapy. It's an R&D company. This chart, showing average market returns, helps clarify the contrast with biotech, where teams of scientists burn through capital.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772643188210 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Oragenics Inc. (OGEN)
Oragenics, Inc. is a biopharmaceutical company developing vaccines and therapeutics for infectious diseases. During the research phase, there is no revenue per employee. The timeline is important as an indicator of the future: a successful vaccine could generate billions in revenue, leading to an explosive increase in this efficacy metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Oragenics-Inc.-OGEN&v=1772643188277 "Sales chart per company employee Oragenics Inc. (OGEN)")
Sales per employee in the market segment - Pharma infections
Oragenics (OGEN) is a clinical-stage biotech focused on developing vaccines against infectious diseases (including COVID-19). They have no commercial revenue. This chart, showing the average yield in the sector, serves as a barometer of OGEN's R&D staff burn rate.
Sales per employee for the market as a whole
Oragenics (OGEN) is a biotech company focused on developing vaccines against infectious diseases. Currently, their business is focused on R&D. This chart reflects their clinical (or preclinical) stage: the company is investing in research and has no commercial revenue yet.
Short shares by company, segment and market as a whole
Shares shorted by company Oragenics Inc. (OGEN)
Oragenics (OGEN) is a biotech company that was trying to develop a COVID vaccine and is now focusing on other infectious diseases. This chart shows the volume of bearish bets. The shorts reflect a bet that the company is late in developing a vaccine and that its new projects will also fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Oragenics-Inc.-OGEN&v=1772643188586 "Short Shares Chart for the Company Oragenics Inc. (OGEN)")
Shares shorted by market segment - Pharma infections
Oragenics (OGEN) is a biotech company specializing in developing vaccines against infectious diseases, including COVID-19. This chart aggregates short positions across the biotech sector. It reflects investor skepticism about companies attempting to enter the crowded COVID-19 vaccine market.
Shares shorted by the overall market
Oragenics, a biotech company that tried to create a COVID vaccine, is now focusing on other infections. This chart reflects the overall market pessimism. Investors are unforgiving of failure. They see a company that was late to the COVID party and is now searching for a new idea, burning through its remaining cash.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Oragenics Inc. (OGEN)
Oragenics is a biotech company that has shifted focus (for example, to intranasal COVID vaccines). This chart is a pure indicator of "news fever." It overheated to the extreme during the pandemic on any hype surrounding vaccines and cooled significantly when that topic faded.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Oragenics-Inc.-OGEN&v=1772643188732 "RSI 14 indicator chart for the company's stock Oragenics Inc. (OGEN)")
RSI 14 Market Segment - Pharma infections
Oragenics (OGEN) is a biotech company focused on developing vaccines against infectious diseases (historically, COVID) and oral health treatments. This chart tracks overall sentiment in the Pharma/Infectious Diseases sector. It helps investors understand whether the entire sector is overheated (as during the pandemic) or oversold amid a decline in interest.
RSI 14 for the overall market
For Oragenics (OGEN), a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OGEN (Oragenics Inc.)
Oragenics is a biotech company focused on developing vaccines (including an intranasal vaccine for COVID-19) and new treatments for infectious diseases. This chart shows the speculative average 12-month price target from analysts, which is almost entirely based on their assessment of clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OGEN-Oragenics-Inc.&v=1772643188867 "A chart showing analyst consensus forecasts for the expected stock price. OGEN (Oragenics Inc.)")
The difference between the consensus estimate and the actual stock price OGEN (Oragenics Inc.)
Oragenics (OGEN) is a biotech company focused on developing vaccines (including nasal vaccines) and new antibiotics. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, which for an R&D company is an estimate of the chances of clinical success and FDA approval.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OGEN-Oragenics-Inc.&v=1772643188940 "A chart showing the difference between the consensus forecast and the actual stock price. OGEN (Oragenics Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma infections
Oragenics is an R&D biotech company focused on developing new vaccines (including intranasal ones) to combat infectious diseases. This chart reflects analysts' overall expectations for the entire infectious pharmaceutical sector. It shows whether experts believe there will be demand for new vaccines after the pandemic.
Analysts' consensus forecast for the overall market share price
Oragenics is a biotech company specializing in developing vaccines against infectious diseases. This is a high-risk sector. This chart reflects the overall market "risk appetite." For OGEN, a clinical-stage company, overall market optimism (the rising chart) is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Oragenics Inc.
Oragenics is a microbiotech company with extensive R&D. They are developing antiviral drugs (for COVID/flu) and vaccines (in the form of a nasal spray). This chart is a pure indicator of their R&D. It doesn't reflect revenue, but rather a speculative assessment of their (very early) scientific progress and their ability to survive and fund their ambitious but risky projects.
AKIMA Market Segment Index - Pharma infections
Oragenics works in the critically important but complex field of infectious diseases, developing vaccines and new antibiotics. The pandemic has highlighted the importance of this sector. This chart allows you to assess how Oragenics stands out: it compares their comprehensive index to the industry average, showing whether they are a leader or a follower.
The AKIM Index for the overall market
Oragenics is a biotech company developing intranasal pharmaceuticals for the treatment of neurological disorders (such as concussion). This chart, which reflects the market average, provides a macro backdrop. It helps assess how OGEN, which has shifted its focus from vaccines to neuroscience, compares to overall trends.
